MTS Europe GmbH, Konstanz, Germany, awaits the CE certification of its high-end lithotripter lithogold380 beginning of 2011. The device approval puts an efficient and tissue-protective therapy for kidney stones within reach of European patients.
MTS situated in Konstanz, Germany, aims to achieve certification of its high-end lithotripter according to EU standards beginning of 2011. The device approval puts the efficient and tissue-protective therapy for kidney stones and other urological indications within reach of European patients. lithogold380 is characterised by a focal area of 20x100mm, a penetration depth of 165mm as well as a maximum treatment pressure of 36,6 MPa. It is proven that the huge therapeutic area reduces the re-treatment rate to less than 7%. Its limited treatment pressure assures a tissue-protective therapy requesting less anaesthesia. Since 2006 MTS shockwave lithotripters have got an excellent reputation with respect to efficacy and practically no adverse effects.
Besides the therapy of urological indications, MTS engages mainly in the non-invasive healing of chronic wounds and skin lesions. In scientific cooperation with renowned universities and research centres, the efficacy of shockwaves in wound management has been extensively proven. Considerable treatment results have been achieved in the treatment of persisting leg ulcers.
MTS Europe GmbH, a company of TRT LLC, USA, specializes in the development and manufacture of extracorporeal shockwave therapy systems, which are used in orthopaedics, traumatology, wound management and urology worldwide. The group is leading in the field of medical shockwave research and becoming market leader in non-invasive therapy of chronic wounds.